[ad_1] Advicenne (Paris: ADVIC), a pharmaceutical company specializing in development of child-friendly therapies for treatment renal disease and neurological diseases, preliminary reports Results of the Phase III Extension Study (B22CS) for ADV7103 …
Read More »Advicenne Confirms the Safety and Efficacy of ADV7103 Following a 24-Month Phase III Extension Study | 3:07:18
